Hormone-dependent prostate cancer
RecruitingDocetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment
Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment
- Disease:Hormone-dependent prostate cancer
- Substances:ApalutamideDocetaxel
France- Participants:18–64 years · 65+ years
- Substances:Apalutamide














